Lung Cancer Trial, Recruiting NCT07166003 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07166003
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 79 years old
  • People who have already received at least two rounds of pre-surgery immunotherapy treatment
  • People who are fully active and able to carry out normal daily activities without any restrictions (a score of 0 on a standard health scale doctors use)
  • People who have complete medical records available, including scan and imaging results

Who may not be able to join:

  • People who have been diagnosed with, or are suspected of having, an active autoimmune disease (a condition where the immune system attacks the body)
  • People whose cancer has specific genetic changes known as EGFR or ALK mutations
  • People who are pregnant or currently breastfeeding
  • People who have previously had cancer treatments such as chemotherapy or radiotherapy
  • People who have had an organ transplant or a stem cell transplant at any point in the past
  • People who have a lung condition such as interstitial pneumonia, pulmonary fibrosis, or severe emphysema (serious lung diseases affecting breathing)
  • People who have diabetes that is not well controlled
  • People who have high blood pressure that is not well controlled

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 8610-87788177

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
20 April 2025
Est. completion
2 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Event-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov